Compare CENX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | ERAS |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2004 | 2021 |
| Metric | CENX | ERAS |
|---|---|---|
| Price | $46.22 | $19.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $65.67 | $14.25 |
| AVG Volume (30 Days) | 1.9M | ★ 5.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $1,893,200,000.00 | N/A |
| Revenue This Year | $20.77 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $14.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.21 | $1.33 |
| 52 Week High | $70.43 | $24.28 |
| Indicator | CENX | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 59.23 |
| Support Level | $43.38 | $17.63 |
| Resistance Level | $47.35 | $21.60 |
| Average True Range (ATR) | 1.93 | 1.29 |
| MACD | 0.81 | -0.16 |
| Stochastic Oscillator | 85.76 | 41.03 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.